New results for baricitinib and ustekinumab use in patients with systemic lupus erythematosus (SLE) were presented in April at the International Congress on Systemic Lupus Erythematosus (LUPUS 2019), which was held in San Francisco. Here, we summarize those results, plus much more from the meeting.
International Congress on Systemic Lupus Erythematosus
The prevalence of systemic lupus erythematosus (SLE) is higher among black patients. They can present with a worsened disease state and mortality rates can be higher. This suggests a need for better therapeutic options, says Jim C. Oates, M.D., of Medical University of South Carolina. In this Q&A, Dr. Oates addresses treatment challenges black patients face.
African American women are disproportionately likely to develop systemic lupus erythematosus, and their disease course is more severe than other demographic groups, says Dr. Edith Williams. In this Q&A, she introduces us to a peer-mentoring program designed to foster self-management.
Patient-doctor narrative matters, says Lisa Rosenbaum, M.D., a cardiologist with Brigham and Women's Hospital in Boston. She shared her insights on patient narratives last month at LUPUS 2019 in San Francisco where she gave the keynote address. Learn more in this Q&A.